Osteopore expands into Latin America with initial regenerative implants sales to Colombia

SYDNEY: Osteopore Limited (ASX: OSX), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale empowering natural tissue regeneration, has successfully expanded into the Latin American market with its first shipment of cranial (skull) regenerative implants to Colombia.

Osteopore’s craniofacial implants are superior, off-the-shelf products that can be manufactured at scale and used in over 1.1m craniofacial procedures globally. The implants dissolve over time to leave only natural healthy bone, and have largely outperformed traditional implant methods in terms of design, post-surgery complications and associated long-term health care costs.

The initial orders were received from Osteopore’s Colombian based distribution partner, Implar SAS, who will promote the technology to their extensive network of hospitals and surgeons across the region. Osteopore’s implants have also successfully been cleared for marketing and sales from Colombia’s regulatory agency, INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos).

The Latin American Bone Graft and Substitutes Market is estimated to be worth US$182 million by 20262 , and while the initial Colombia sales are not material in terms of revenue, its significance represent an endorsement of Osteopore’s continued strategy to penetrate new markets and drive uptake amongst surgeons.

With regulatory access and operation in more than 20 countries and autonomous regions such as the US, Europe, Asia and Australia, Osteopore aims to gain additional regulatory access in new markets, and continue to execute on its vision to become the standard-of-care for bone and tissue regeneration globally.

Osteopore Executive Chairman, Mark Leong said; “Achieving first sales into Latin America is a fantastic milestone for the company, as surgeons around the world increasingly realise the benefits of Osteopore products. We plan to harness this opportunity and work towards the necessary regulatory approval to expand sales in additional Latin American jurisdictions, as well as continue building an economic moat around the Company’s novel technology.”

Osteopore expands into Latin America with initial regenerative implants sales to Colombia


About the author

Leave a Reply

Your email address will not be published. Required fields are marked *